These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17321043)

  • 1. Fluorescence in situ hybridization to evaluate dysplasia in Barrett's esophagus: a pilot study.
    Cestari R; Villanacci V; Rossi E; Della Casa D; Missale G; Conio M; Grigolato P; Bassotti G
    Cancer Lett; 2007 Jun; 251(2):278-87. PubMed ID: 17321043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population.
    Rygiel AM; van Baal JW; Milano F; Wang KK; ten Kate FJ; Fockens P; Rosmolen WD; Bergman JJ; Peppelenbosch MP; Krishnadath KK
    Cancer; 2007 May; 109(10):1980-8. PubMed ID: 17385213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
    Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
    Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression.
    Weston AP; Banerjee SK; Sharma P; Tran TM; Richards R; Cherian R
    Am J Gastroenterol; 2001 May; 96(5):1355-62. PubMed ID: 11374668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression.
    Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR
    Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
    Lim CH; Treanor D; Dixon MF; Axon AT
    Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
    Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
    Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
    Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
    Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation.
    Polkowski W; Baak JP; van Lanschot JJ; Meijer GA; Schuurmans LT; Ten Kate FJ; Obertop H; Offerhaus GJ
    J Pathol; 1998 Feb; 184(2):161-8. PubMed ID: 9602707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens.
    Rygiel AM; Milano F; Ten Kate FJ; de Groot JG; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Genes Chromosomes Cancer; 2008 May; 47(5):396-404. PubMed ID: 18265409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
    Dorer R; Odze RD
    Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus.
    van Sandick JW; Baak JP; van Lanschot JJ; Polkowski W; ten Kate FJ; Obertop H; Offerhaus GJ
    J Pathol; 2000 Feb; 190(2):177-83. PubMed ID: 10657016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are ulcers a marker for invasive carcinoma in Barrett's esophagus? Data from a diagnostic variability study with clinical follow-up.
    Montgomery E; Bronner MP; Greenson JK; Haber MM; Hart J; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Goldblum JR
    Am J Gastroenterol; 2002 Jan; 97(1):27-31. PubMed ID: 11808966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.
    Montgomery E; Goldblum JR; Greenson JK; Haber MM; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Zahurak ML; Hart J
    Hum Pathol; 2001 Apr; 32(4):379-88. PubMed ID: 11331954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oncogene amplification and genetic heterogeneity in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus].
    Walch A; Bink K; Hutzler P; Zitzelsberger H; Braselmann H; Aubele M; Höfler H; Werner M
    Verh Dtsch Ges Pathol; 2001; 85():257-63. PubMed ID: 11894407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues.
    Fang M; Lew E; Klein M; Sebo T; Su Y; Goyal R
    Am J Gastroenterol; 2004 Oct; 99(10):1887-94. PubMed ID: 15447746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized crossover study that used methylene blue or random 4-quadrant biopsy for the diagnosis of dysplasia in Barrett's esophagus.
    Lim CH; Rotimi O; Dexter SP; Axon AT
    Gastrointest Endosc; 2006 Aug; 64(2):195-9. PubMed ID: 16860068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
    Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
    Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.